A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Mise à jour : Il y a 4 ans
Référence : NCT00658567

Femme et Homme

Extrait

This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.


Critère d'inclusion

  • Parkinson's Disease Psychosis


Liens